Top Markets
Coin of the day
Acrivon Therapeutics, Inc. Common Stock Acrivon Therapeutics, Inc. Common Stock

Acrivon Therapeutics, Inc. Common Stock

ACRV
Ранг среди акций #22054
Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical... Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool. It is instrumental in developing drug-specific OncoSignature companion diagnostics, which are designed to pinpoint individuals most likely to benefit from the company's therapeutic candidates. Acrivon's flagship clinical asset is ACR-368, a selective small molecule inhibitor that targets both CHK1 and CHK2. This candidate is currently undergoing a potentially pivotal Phase 2 trial for a range of advanced tumor types, notably including platinum-resistant ovarian, endometrial, and bladder cancers. Beyond its lead program, the company is also cultivating several early-stage pipeline programs. These initiatives concentrate on crucial regulatory points within the DNA damage response and cell cycle regulation pathways, specifically identifying targets such as the protein kinases WEE1 and PKMYT1. Established in 2018, Acrivon Therapeutics, Inc. maintains its headquarters in Watertown, Massachusetts.
Цена акции
$2.23
Последняя синхронизация: 2026-08-21
Рыночная капитализация
$95.23M
Изменение (1 день)
1.14%
Изменение (1 год)
63.60%
Страна
US
Торговля Acrivon Therapeutics, Inc. Common Stock (ACRV)

Категория

Выручка компании Acrivon Therapeutics, Inc. Common Stock (ACRV)
Выручка на Aug 2026 TTM: 0
Согласно последним финансовым отчетам Acrivon Therapeutics, Inc. Common Stock, текущая выручка компании (TTM) составляет 0. В 2026 году компания получила выручку 0 равна выручке в 2026 году, которая составила 0. Выручка — это общий доход, который компания получает от продажи товаров или услуг. В отличие от прибыли, расходы не вычитаются.
История выручки Acrivon Therapeutics, Inc. Common Stock с 2026 по 2026
Выручка на конец каждого года
Год Выручка Изменить
Недостаточно данных для указанных дат.
Выручка аналогичных компаний или конкурентов
Компания Выручка Разница в выручке Страна
$12.62B -
US
$6.02B -
NL
$2.23B -
US
$15.74B -
AU
- -
CH